Results 61 to 70 of about 129,296 (209)

Pancreatic-Polypeptide in the Human Pancreas: Expression and Quantitative Variation During Development and in Ductal Adenocarcinoma

Acta Medica, 2003
Aim: To determine the immunoreactivity of pancreatic-polypeptide (PP) during the development of the human fetal pancreas and ductal pancreatic adenocarcinoma, given that, PP positive cells were demonstrated either into its embryonic anlage or into ...
Demetrio Tamiolakis, Constantine Simopoulos, Athanasia Kotini, Ioannis Venizelos, Theodoros Jivannakis, Nikolaos Papadopoulos   +5 more
doaj   +1 more source

Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice. [PDF]

, 2019
We examined the impact of statins on Yes-associated Protein (YAP) localization, phosphorylation and transcriptional activity in human and mouse pancreatic ductal adenocarcinoma (PDAC) cells.
Chang, Hui-Hua, Eibl, Guido, Hao, Fang, Rozengurt, Enrique, Sinnett-Smith, James, Wang, Jing, Xu, Qinhong, Yu, Shuo   +7 more
core   +2 more sources

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source

Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model. [PDF]

, 2018
Pancreatic ductal adenocarcinoma (PDAC) is a particularly deadly disease. Chronic conditions, including obesity and type-2 diabetes are risk factors, thus making PDAC amenable to preventive strategies.
Chang, Hui-Hua, Chou, Caroline Ei Ne, Dawson, David W, Eibl, Guido, French, Samuel, Hao, Fang, Hines, O Joe, Moro, Aune, Rozengurt, Enrique, Schmidt, Andrea I, Sinnett-Smith, James   +10 more
core   +2 more sources

Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma

World Journal of Surgical Oncology, 2021
Background Frailty is an important consideration for older patients undergoing surgery. We aimed to investigate whether frailty could be a prognostic factor in patients with pancreatic ductal adenocarcinoma who underwent pancreatic resection. Methods One
Shinichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saito, Katsuki Miyazaki, Takuya Tokunaga, Masaaki Nishi   +8 more
doaj   +1 more source

Metabolic Dependencies in Pancreatic Cancer. [PDF]

, 2018
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a long-term survival rate under 10%. Available cytotoxic chemotherapies have significant side effects, and only marginal therapeutic efficacy. FDA approved drugs currently used against
Brody, Jonathan R., Vaziri-Gohar, Ali, Winter, Jordan M., Zarei, Mahsa   +3 more
core   +1 more source

mTORC2 signaling drives the development and progression of pancreatic cancer [PDF]

, 2016
mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the mTORC1 complex.
Bardeesy, Nabeel, Barry, Simon T., Driscoll, David R., Evans, T.R. Jeffry, Gay, David M., Gopinathan, Aarthi, Hall, Michael N., Jacob, Wright, Jodrell, Duncan I., Karim, Saadia A., Klimstra, David S., Lewis, Brian C., Mizukami, Yusuke, Morton, Jennifer P., Quattrochi, Brian J., Sano, Makoto, Sansom, Owen J., Yu, Jun   +17 more
core   +1 more source

PSMD11 and PSMD14 may serve as novel biomarkers for the prognosis of pancreatic ductal adenocarcinoma

Frontiers in Oncology
BackgroundThe ubiquitin proteasome system is involved in the regulation of cellular gene transcription and cellular receptor function through the degradation of proteins, thus affecting tumorigenesis and development.
Yan-Hui Yang, Zhe-Hua Xing, Hao Wang, Chi Zhang, Yu-Bo Liu, Qian-Qian Bai, Fang-Fei Liu, Wei-Feng Liu, Jun-Chuan Yang, Da-Huan Li, Hua Fan   +10 more
doaj   +1 more source

LncRNA PVT1 triggers Cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis

Molecular Cancer, 2018
Background Defective autophagy is thought to contribute to the pathogenesis of many diseases, including cancer. Human plasmacytoma variant translocation 1 (PVT1) is an oncogenic long non-coding RNA that has been identified as a prognostic biomarker in ...
Fengting Huang, Wenying Chen, Juanfei Peng, Yuanhua Li, Yanyan Zhuang, Zhe Zhu, Chunkui Shao, Wanling Yang, Herui Yao, Shineng Zhang   +9 more
doaj   +1 more source

Regulation of Proliferation by a Mitochondrial Potassium Channel in Pancreatic Ductal Adenocarcinoma Cells [PDF]

, 2017
Previous results link the mitochondrial potassium channel Kv1.3 (mitoKv1.3) to the regulation of apoptosis. By synthesizing new, mitochondria-targeted derivatives (PAPTP and PCARBTP) of PAP-1, a specific membrane-permeant Kv1.3 inhibitor, we have ...
Amigorena, Arcangeli, Beeton, Cahalan, Checchetto, Chittajallu, Cholo, Cidad, Comes, Connor, Deutsch, Diebold, Diwakarla, Doyle, Erdogan, Esteras, Fraser, Ghiani, Heginbotham, Hinz, Hu, Jang, Koren, Leanza, Leanza, Leanza, Lin, Long, Lu, Malinska, Manago, Nilius, Pardo, Peruzzo, Ralph, Ralph, Rauer, Shieh, Siegel, Szabo, Szabo, Tegla, Tonks, Urrego, Van Rensburg, Xu, Zaccagnino, Zhou, Zucca   +48 more
core   +2 more sources